Chronic kidney diseases affect a staggering 1 in 7 individuals worldwide, accounting for nearly 400 million people globally. Approximately 30% of these conditions are genetic in nature, such as Polycystic Kidney Disease, among others. Sadly, many CKD patients progress to end-stage renal failure, necessitating weekly or more frequent dialysis sessions, which severely compromises their quality of life. Furthermore, the need for kidney transplantation is pressing, yet less than three percent of patients receive this life-saving intervention. Living with CKD exacts a heavy toll, inflicting physical, emotional, and financial hardships. Helex is dedicated to pioneering a new class of curative therapies for these patients.